EUVIMEDEUVIMED entdecken
Open Access

COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment

David Salisbury iD, Jeffrey V Lazarus iD, Nancy Waite iD, Clara Lehmann iD, Sumitra Sri Bhashyam iD, Marie de la Cruz iD, Beth Hahn iD, Matthew D Rousculp iD, Paolo Bonanni iD

JMIR Public Health and Surveillance · 2024

DOI: 10.2196/57242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JMIR Public Health and Surveillance, 2024. Verfasst von David Salisbury und 8 weiteren Autor:innen. Beteiligte Einrichtung: Programme for Global Health, Royal Institute of International Affairs, Chatham House, London, United Kingdom. Hauptthemen laut MEDLINE: COVID-19 Vaccines, Choice Behavior, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite strong evidence supporting COVID-19 vaccine efficacy and safety, a proportion of the population remains hesitant to receive immunization. Discrete choice experiments (DCEs) can help assess preferences and decision-making drivers.

Objective

We aim to (1) elicit preferences for COVID-19 vaccines in Canada, Germany, the United Kingdom, and the United States; (2) understand which vaccine attributes people there value; and (3) gain insight into the choices that different population subgroups make regarding COVID-19 vaccines.

Methods

Participants in the 2019nCoV-408 study were aged ≥18 years; self-reported antivaccinationists were excluded. A DCE with a series of 2 hypothetical vaccine options was embedded into a survey to determine participant treatment preferences (primary objective). Survey questions covered vaccine preference, previous COVID-19 experiences, and demographics, which were summarized using descriptive statistics to understand the study participants’ backgrounds. In the DCE, participants were provided choice pairs: 1 set with and 1 without an “opt-out” option. Each participant viewed 11 unique vaccine profiles. Vaccine attributes consisted of type (messenger RNA or protein), level of protection against any or severe COVID-19, risk of side effects (common and serious), and potential coadministration of COVID-19 and influenza vaccines. Attribute level selections were included for protection and safety (degree of effectiveness and side effect risk, respectively). Participants were stratified by vaccination status (unvaccinated, or partially or fully vaccinated) and disease risk group (high-risk or non–high-risk). A conditional logit model was used to analyze DCE data to estimate preferences of vaccine attributes, with the percentage relative importance calculated to allow for its ranking. Each model was run twice to account for sets with and without the opt-out options.

Results

The mean age of participants (N=2000) was 48 (SD 18.8) years, and 51.25% (1025/2000) were male. The DCE revealed that the most important COVID-19 vaccine attributes were protection against severe COVID-19 or any severity of COVID-19 and common side effects. Protection against severe COVID-19 was the most important attribute for fully vaccinated participants, which significantly differed from the unvaccinated or partially vaccinated subgroup (relative importance 34.8% vs 30.6%; P=.049). Avoiding serious vaccine side effects was a significantly higher priority for the unvaccinated or partially versus fully vaccinated subgroup (relative importance 10.7% vs 8.2%; P=.044). Attributes with significant differences in the relative importance between the high-risk versus non–high-risk subgroups were protection against severe COVID-19 (38.2% vs 31.5%; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesChoice BehaviorCOVID-19HumansCanadaMaleUnited StatesFemaleUnited KingdomAdultMiddle AgedGermanyPatient PreferenceAgedSurveys and QuestionnairesYoung AdultAdolescent

Stichwörter der Autor:innen

COVID vaccinationCOVID-19SARS-CoV-2antivaccinediscrete choice experimentimmunizationinformed decision-makingpreference elicitationvaccine hesitancyvaccine side effects

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Programme for Global Health, Royal Institute of International Affairs, Chatham House, London, United Kingdom.
  • Graduate School of Public Health and Health Policy (CUNY SPH), City University of New York, New York, NY, United States.
  • Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Barcelona, Spain.
  • School of Pharmacy, University of Waterloo, Ontario, ON, Canada.
  • Department of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • ICON Insights, Evidence and Value-Patient Centered Outcomes, Reading, United Kingdom.

ORCID-Profile: David Salisbury, Jeffrey V Lazarus, Nancy Waite, Clara Lehmann, Sumitra Sri Bhashyam, Marie de la Cruz, Beth Hahn, Matthew D Rousculp, Paolo Bonanni

Zitieren

APA

Salisbury, D., Lazarus, J. V., Waite, N., Lehmann, C., Sri Bhashyam, S., de la Cruz, M., Hahn, B., Rousculp, M. D., & Bonanni, P. (2024). COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment. JMIR Public Health and Surveillance. https://doi.org/10.2196/57242

Vancouver

Salisbury D, Lazarus JV, Waite N, Lehmann C, Sri Bhashyam S, de la Cruz M, et al. COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment. JMIR Public Health and Surveillance. 2024. doi:10.2196/57242

BibTeX
@article{Salisbury2024,
  author = {Salisbury, David and Lazarus, Jeffrey V and Waite, Nancy and Lehmann, Clara and Sri Bhashyam, Sumitra and de la Cruz, Marie and Hahn, Beth and Rousculp, Matthew D and Bonanni, Paolo},
  title = {COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment},
  journal = {JMIR Public Health and Surveillance},
  year = {2024},
  doi = {10.2196/57242}
}
Kostenlos starten →